Clinical Trials Logo

Stomach Neoplasms clinical trials

View clinical trials related to Stomach Neoplasms.

Filter by:

NCT ID: NCT03813784 Active, not recruiting - Gastric Cancer Clinical Trials

A Study to Evaluate SHR-1210 in Combination With Capecitabine + Oxaliplatin Sequenced by SHR-1210 + Apatinib as First-line Therapy in Treatment of Advanced Gastric Cancer

Start date: March 7, 2019
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, multi-center, phase III trial to evaluate the efficacy and safety of SHR-1210 plus capecitabine and oxaliplatin sequenced by apatinib with or without SHR-1210 versus capecitabine and oxaliplatin as first-line therapy in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

NCT ID: NCT03802097 Completed - Gastric Cancer Clinical Trials

Study About no Antimicrobial Prophylaxis in Totally Laparoscopic Distal Gastrectomy

KSWEET-03
Start date: December 27, 2018
Phase: N/A
Study type: Interventional

Laparoscopic gastrectomy has fewer infectious complications compared to open surgery. Recently, the incidence of postoperative infectious complications was greatly reduced due to the development of surgical techniques and improvement of prevention and control of surgical infection. Previous multicenter, phase II study (KSWEET-01) revealed that the incidence of infectious complications of laparoscopic gastrectomy without prophylactic antibiotics was not significantly higher than previously reported data. Therefore, this study aim to prove the safety of totally laparoscopic distal gastrectomy without prophylactic antibiotics, specially reference to the postoperative infectious complications.

NCT ID: NCT03801668 Recruiting - Gastric Cancer Clinical Trials

Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Start date: March 8, 2019
Phase: Phase 3
Study type: Interventional

It is a trial to compare the efficacy and safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus S-1 (SOX) as first-line treatment in advanced or recurrent gastric adenocarcinoma.

NCT ID: NCT03793335 Enrolling by invitation - Colorectal Cancer Clinical Trials

Individually Tailored Strategies for the Precision Prevention of Gastric Cancer and Colorectal Cancer in the Community

Start date: April 14, 2019
Phase:
Study type: Observational

Gastric cancer is a global health threat. Helicobacter pylori is now recognized as the main risk factor that initiates this process; hence, H. pylori eradication has been considered the most effective method to ameliorate the burden of gastric cancer. Serum pepsinogen levels reveal the current atrophy of the stomach and predict gastric cancer risk. A risk prediction model with the combination of H. pylori infection and serum pepsinogen level could identify the highest-risk gastric cancer patients. Colorectal cancers (CRC) rank second and third as the leading causes of cancer-related death in men and women, respectively. For CRC prevention, a two-stage approach using the fecal immunochemical test (FIT) is popular; besides, the FIT levels may serve as a guide for priority setting in prompting residents to undergo colonoscopy. Therefore, the effectiveness and utility of aggressive referral confirmatory diagnosis protocol in a colorectal cancer screening program for those with high FIT levels urgently need to evaluate.

NCT ID: NCT03788226 Recruiting - Clinical trials for Gastric Cancer Stage III

A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer

Start date: February 1, 2019
Phase: Phase 3
Study type: Interventional

FNF-014 is a randomised, open-label, multicentre, parallel-group, phase 3 study in China to prove superiority of POF over S-1/docetaxel in postoperative adjuvant setting for pStage III gastric adenocarcinoma (including adenocarcinoma of the gastrooesophageal junction).

NCT ID: NCT03787537 Completed - Colorectal Cancer Clinical Trials

Nutritional Status and Nutrient Supply in Hospitalised Surgical Patients

Start date: August 1, 2017
Phase:
Study type: Observational

Prospective single arm, single center observational study to assess the nutritional status and the nutrient supply during hospitalization for elective gastrointestinal surgery.

NCT ID: NCT03784040 Recruiting - Gastric Cancer Clinical Trials

Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.

da VINci
Start date: February 21, 2019
Phase: Phase 1
Study type: Interventional

The primary hypothesis is that cancer vaccine can convert non-immunogenic gastric cancer into immunogenic phenotype susceptible to PD1 inhibition. This would lead to an improved radiological response rate and favorable immune contexture for immune checkpoint blockade

NCT ID: NCT03780439 Completed - Gastric Cancer Clinical Trials

Procalcitonin to Predict Infection After Gastrectomy for Gastric Cancer

Start date: June 1, 2018
Phase:
Study type: Observational

To investigate the diagnostic accuracy of procalcitonin as an early predictor of infection after radical gastrectomy for gastric cancer.

NCT ID: NCT03778710 Completed - Gastric Cancer Clinical Trials

Effect of Lymph Node Ratio in Gastric Cancer to Determine Recurrence Rate After Curative Resection

Start date: December 18, 2018
Phase:
Study type: Observational

D2 gastrectomy is standard treatment of early gastric cancer in Japan but in other countries there is still some discord, especially in Europe and North America. Although the quantity of metastasis cancer in lymph node defines survival regardless of which country the patient is treated, the total number of lymph nodes harvested is an important factor to predict accurate staging and/or D2 gastrectomy. Both of the number total lymph nodes and the metastasis lymph node status in gastric cancer are important factors to decide each prognosis. This study evaluated the correlation between total lymph nodes retrieved and metastasis node by lymph node ratio (LNR) status to determine the recurrence rate after curative resection of gastric

NCT ID: NCT03777540 Completed - Gastric Cancer Clinical Trials

Gastric Cancer Surgery in Elderly Patients

GCSEP
Start date: January 1, 2010
Phase:
Study type: Observational

Gastric cancer is most frequent after the fifth decade of life. Surgical risk is higher in aged population because of general health condition may affect the postoperative result. Aim of the study was to identify risk factors for post-operative mortality in octogenarian patients who underwent surgery for gastric cancer.